KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Net Margin (2016 - 2025)

Historic Net Margin for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to 98.85%.

  • Pacific Biosciences Of California's Net Margin rose 530900.0% to 98.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 325.8%, marking a year-over-year decrease of 981100.0%. This contributed to the annual value of 201.18% for FY2024, which is 482100.0% down from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Net Margin of 98.85% as of Q3 2025, which was up 530900.0% from 105.44% recorded in Q2 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Net Margin peaked at 47.42% during Q3 2021, and registered a low of 1146.81% during Q1 2025.
  • Its 5-year average for Net Margin is 221.53%, with a median of 151.94% in 2024.
  • The largest annual percentage gain for Pacific Biosciences Of California's Net Margin in the last 5 years was 3758300bps (2025), contrasted with its biggest fall of -9453700bps (2025).
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Net Margin stood at 192.48% in 2021, then crashed by -60bps to 308.5% in 2022, then surged by 54bps to 140.55% in 2023, then soared by 104bps to 6.04% in 2024, then tumbled by -1735bps to 98.85% in 2025.
  • Its last three reported values are 98.85% in Q3 2025, 105.44% for Q2 2025, and 1146.81% during Q1 2025.